Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Aegerion Pharma Inc (AEGR) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 55,250
  • Shares Outstanding, K 29,540
  • Annual Sales, $ 239,890 K
  • Annual Income, $ -73,340 K
  • 36-Month Beta 0.50
  • Price/Sales 0.23
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.07
  • Most Recent Earnings -0.37 on 11/03/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.50 +31.33%
on 11/07/16
2.34 -15.81%
on 11/29/16
+0.14 (+7.65%)
since 10/28/16
3-Month
1.50 +31.33%
on 11/07/16
3.35 -41.19%
on 09/29/16
+0.33 (+20.12%)
since 08/29/16
52-Week
1.23 +60.16%
on 06/14/16
10.85 -81.84%
on 12/24/15
-8.49 (-81.17%)
since 11/27/15

Most Recent Stories

More News
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)

-- Transaction provides new royalty and potential milestone revenues, opportunity to reduce cost structure, and continuity of patient access to lomitapide -

Aegerion Pharmaceuticals, Inc. and QLT Inc. Complete Merger Transaction; QLT to Change Name to Novelion Therapeutics Inc.

-- Transaction creates strong, diversified rare-disease focused portfolio

Aegerion's Juxtapid Gets Pricing Authorization in Japan

Aegerion Pharmaceuticals, Inc. (AEGR) announced that Japan's Ministry of Health, Labor & Welfare (MHLW) has approved the pricing authorization of its first product, Juxtapid.

QLT Announces Shareholder Approval of Matters Related to Strategic Merger and Record Date for Distribution of Warrants

QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT") announced today certain matters relating to the previously announced transactions (the "Transactions") contemplated in connection with an agreement and plan of...

Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3

Aegerion (AEGR) reported a loss of 46 cents per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 67 cents.

Aegerion Pharmaceuticals Announces Third Quarter 2016 Financial Results

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced...

Aegerion Pharmaceuticals Appoints John Orloff, M.D., as Executive Vice President, Head of R&D

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today...

QLT's (QLTI) Reports In-Line Q3 Loss, Merger in Focus

QLT Inc. (QLTI) reported a loss of 11 cents per share in the third quarter of 2016.

Research Reports Coverage on Biotech Stocks -- Merrimack Pharma, Aurinia Pharma, Aegerion Pharma, and TG Therapeutics

Stock-Callers.com has on its radar four these Biotech equities, namely: Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Aegerion Pharmaceuticals Inc. (NASDAQ:...

Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is...

See More

Support & Resistance

2nd Resistance Point 2.54
1st Resistance Point 2.25
Last Price 1.97
1st Support Level 1.77
2nd Support Level 1.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.